J 2021

Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-D-Aspartate receptors

GORECKI, Lukas, Anna MISIACHNA, Jiří DAMBORSKÝ, Rafael DOLEZAL, Jan KORABECNY et. al.

Basic information

Original name

Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-D-Aspartate receptors

Authors

GORECKI, Lukas (203 Czech Republic), Anna MISIACHNA (203 Czech Republic), Jiří DAMBORSKÝ (203 Czech Republic, guarantor, belonging to the institution), Rafael DOLEZAL (203 Czech Republic), Jan KORABECNY (203 Czech Republic), Lada CEJKOVA (203 Czech Republic), Kristina HAKENOVA (203 Czech Republic), Marketa CHVOJKOVA (203 Czech Republic), Jana KARASOVA ZDAROVA (203 Czech Republic), Lukas PRCHAL (203 Czech Republic), Martin NOVAK (203 Czech Republic), Marharyta KOLCHEVA (203 Czech Republic), Stepan KORTUS (203 Czech Republic), Karel VALES (203 Czech Republic), Martin HORAK (203 Czech Republic) and Ondřej SOUKUP (203 Czech Republic)

Edition

European Journal of Medicinal Chemistry, PARIS, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, 0223-5234

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30107 Medicinal chemistry

Country of publisher

France

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.088

RIV identification code

RIV/00216224:14310/21:00122286

Organization unit

Faculty of Science

UT WoS

000646945500020

Keywords in English

QSAR; Acetylcholinesterase; Electrophysiology; Glutamate receptor; Ion channel; Pharmacology; in vivo; Tacrine

Tags

Tags

International impact, Reviewed
Změněno: 16/2/2023 12:42, Mgr. Michaela Hylsová, Ph.D.

Abstract

V originále

Tacrine is a classic drug whose efficacy against neurodegenerative diseases is still shrouded in mystery. It seems that besides its inhibitory effect on cholinesterases, the clinical benefit is co-determined by NMDAR-antagonizing activity. Our previous data showed that the direct inhibitory effect of tacrine, as well as its 7-methoxy derivative (7-MEOTA), is ensured via a "foot-in-the-door" open-channel blockage, and that interestingly both tacrine and 7-MEOTA are slightly more potent at the GluN1/GluN2A receptors when compared with the GluN1/GluN2B receptors. Here, we report that in a series of 30 novel tacrine derivatives, designed for assessment of structure-activity relationship, blocking efficacy differs among different compounds and receptors using electrophysiology with HEK293 cells expressing the defined types of NMDARs. Selected compounds (4 and 5) potently inhibited both GluN1/GluN2A and GluN1/GluN2B receptors; other compounds (7 and 23) more effectively inhibited the GluN1/GluN2B receptors; or the GluN1/GluN2A receptors (21 and 28). QSAR study revealed statistically significant model for the data obtained for inhibition of GluN1/Glu2B at -60 mV expressed as IC50 values, and for relative inhibition of GluN1/Glu2A at +40 mV caused by a concentration of 100 mu M. The models can be utilized for a ligand-based virtual screening to detect potential candidates for inhibition of GluN1/Glu2A and/or GluN1/Glu2B subtypes. Using in vivo experiments in rats we observed that unlike MK-801, the tested novel compounds did not induce hyperlocomotion in open field, and also did not impair prepulse inhibition of startle response, suggesting minimal induction of psychotomimetic side effects. We conclude that tacrine derivatives are promising compounds since they are centrally available subtype-specific inhibitors of the NMDARs without detrimental behavioral side-effects.